NewswireToday - /newswire/ -
Palo Alto, CA, United States, 2007/02/07 - The company's Generex Oral-lyn™, a breakthrough oral insulin spray technology for the treatment of Type-1 and Type-2 diabetes, offers an ideal and noninvasive route for insulin delivery.
Frost & Sullivan selected Generex Biotechnology Corporation (Nasdaq: GNBT-News) as the recipient of the 2006 Frost & Sullivan Award for Technology Innovation in the field of diabetic therapies.
Generex's solution plugs the deficiencies of other alternative delivery modes such as insulin patches, insulin pumps, and inhaled insulin, which are not commonly available or cost effective, and may have treatment limitations.
The company uses the buccal drug delivery technology, which it has been pioneering for years, to develop a liquid formulation of human insulin that can be sprayed into the mouth using its proprietary Rapid Mist™ device.
"The main advantage of this technology is that it ensures absorption is limited to the mouth with no entry to the lungs, thus eliminating the risk of pulmonary inflammations," says Frost & Sullivan Research Analyst Sangeetha Prabakar. "Also, unique features such as rapid insulin absorption and shorter activity make Generex Oral-lyn™ an ideal prandial insulin, which can be conveniently administered immediately after meals and causes minimal occurrence of hypoglycemia."
Generex Oral-lyn™ is a dual-use product. For prediabetic people, it serves as a preventive pharmacological agent to delay the onset of diabetes and for patients with type II diabetes; it helps to postpone diabetic complications. It also significantly reduces the enormous costs associated with diabetes therapies and costs resulting from diabetes complications.
"Since the sprayed insulin is absorbed through the buccal mucosa, Generex Oral-lyn™ can prove an effective alternative to painful mealtime insulin injections, thus improving patient compliance -- especially among children," notes Prabakar. "Generex is highly focused toward the commercialization of a novel and painless oral insulin therapy, which is sure to revolutionize the insulin market and the treatment of diabetes."
Presently, Generex Oral-lyn™ is already on the market in South America. The Company is also preparing for a pivotal Phase III study in the USA and worldwide.
Each year Frost & Sullivan presents this Award to the company that has carried out new research, which has resulted in innovations that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. The Award recognizes the quality and depth of a company's research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavor.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
About Generex Biotechnology Corporation
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.